215 related articles for article (PubMed ID: 19620849)
1. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia.
Kim SW; Shin IS; Kim JM; Lee JH; Lee YH; Yang SJ; Yoon JS
Clin Neuropharmacol; 2009; 32(5):243-9. PubMed ID: 19620849
[TBL] [Abstract][Full Text] [Related]
2. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
Kim SW; Shin IS; Kim JM; Bae KY; Yang SJ; Yoon JS
Clin Neuropharmacol; 2010 May; 33(3):121-5. PubMed ID: 20502130
[TBL] [Abstract][Full Text] [Related]
4. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
[TBL] [Abstract][Full Text] [Related]
5. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering.
Takeuchi H; Suzuki T; Uchida H; Nakajima S; Nomura K; Kikuchi T; Manki H; Watanabe K; Kashima H
J Clin Psychopharmacol; 2008 Oct; 28(5):540-3. PubMed ID: 18794650
[TBL] [Abstract][Full Text] [Related]
6. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
Lin CH; Lin SH; Jang FL
J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
[TBL] [Abstract][Full Text] [Related]
7. Effect of aripiprazole on verbal memory and fluency in schizophrenic patients : results from the ESCAPE study.
Bervoets C; Morrens M; Vansteelandt K; Kok F; de Patoul A; Halkin V; Pitsi D; Constant E; Peuskens J; Sabbe B
CNS Drugs; 2012 Nov; 26(11):975-82. PubMed ID: 23018547
[TBL] [Abstract][Full Text] [Related]
8. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.
Chen CK; Huang YS; Ree SC; Hsiao CC
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1495-9. PubMed ID: 20732372
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R
Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566
[TBL] [Abstract][Full Text] [Related]
10. The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia.
Kim SW; Yoon JS; Kim YS; Ahn YM; Kim CE; Go HJ; Chee IS; Jung SW; Chung YC; Kim YD; Joe S; Lee J; Kwon YJ; Yoon BH; Jae YM
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):228-35. PubMed ID: 22516251
[TBL] [Abstract][Full Text] [Related]
11. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.
Kim SW; Chung YC; Lee YH; Lee JH; Kim SY; Bae KY; Kim JM; Shin IS; Yoon JS
Int Clin Psychopharmacol; 2012 Sep; 27(5):267-74. PubMed ID: 22809972
[TBL] [Abstract][Full Text] [Related]
12. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
Stip E; Tourjman V
Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
[TBL] [Abstract][Full Text] [Related]
13. A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.
Takekita Y; Kato M; Wakeno M; Sakai S; Suwa A; Nishida K; Okugawa G; Kinoshita T
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():110-4. PubMed ID: 23022672
[TBL] [Abstract][Full Text] [Related]
14. Association between attitude toward medication and neurocognitive function in schizophrenia.
Kim SW; Shin IS; Kim JM; Yang SJ; Shin HY; Yoon JS
Clin Neuropharmacol; 2006; 29(4):197-205. PubMed ID: 16855421
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
McEvoy JP; Daniel DG; Carson WH; McQuade RD; Marcus RN
J Psychiatr Res; 2007 Dec; 41(11):895-905. PubMed ID: 17631314
[TBL] [Abstract][Full Text] [Related]
16. Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study.
Schüle C; Baghai TC; Eser D; Hecht S; Hermisson I; Born C; Häfner S; Nothdurfter C; Rupprecht R
World J Biol Psychiatry; 2007; 8(2):112-22. PubMed ID: 17455104
[TBL] [Abstract][Full Text] [Related]
17. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study.
Ryckmans V; Kahn JP; Modell S; Werner C; McQuade RD; Kerselaers W; Lissens J; Sanchez R
Pharmacopsychiatry; 2009 May; 42(3):114-21. PubMed ID: 19452380
[TBL] [Abstract][Full Text] [Related]
18. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
Kane JM; Sanchez R; Perry PP; Jin N; Johnson BR; Forbes RA; McQuade RD; Carson WH; Fleischhacker WW
J Clin Psychiatry; 2012 May; 73(5):617-24. PubMed ID: 22697189
[TBL] [Abstract][Full Text] [Related]
19. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study.
Mitsonis CI; Dimopoulos NP; Mitropoulos PA; Kararizou EG; Katsa AN; Tsakiris FE; Katsanou MN
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):373-7. PubMed ID: 17092620
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
